Leerink Partnrs Estimates Atyr PHARMA FY2024 Earnings

Atyr PHARMA INC (NASDAQ:ATYR) – Analysts at Leerink Partnrs issued their FY2024 EPS estimates for Atyr PHARMA in a note issued to investors on Tuesday, February 18th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings per share of ($0.89) for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Atyr PHARMA’s Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.71) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at $0.16 EPS, FY2028 earnings at $1.29 EPS and FY2029 earnings at $1.82 EPS.

Several other analysts have also recently commented on the company. Cantor Fitzgerald initiated coverage on Atyr PHARMA in a research report on Monday, January 6th. They issued an “overweight” rating for the company. Leerink Partners started coverage on Atyr PHARMA in a research note on Tuesday. They issued an “outperform” rating and a $16.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Trading Down 2.5 %

Atyr PHARMA stock opened at $4.32 on Thursday. Atyr PHARMA has a 52 week low of $1.42 and a 52 week high of $4.66. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The firm has a market capitalization of $362.63 million, a price-to-earnings ratio of -4.60 and a beta of 1.10. The company has a 50 day moving average price of $3.61 and a 200 day moving average price of $2.87.

Institutional Trading of Atyr PHARMA

Hedge funds and other institutional investors have recently modified their holdings of the company. Federated Hermes Inc. purchased a new position in Atyr PHARMA in the fourth quarter valued at about $53,093,000. Point72 Asset Management L.P. acquired a new stake in shares of Atyr PHARMA during the 4th quarter valued at about $17,677,000. Tikvah Management LLC bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at approximately $8,908,000. Woodline Partners LP acquired a new position in Atyr PHARMA in the fourth quarter worth approximately $6,092,000. Finally, Alyeska Investment Group L.P. acquired a new position in Atyr PHARMA in the fourth quarter worth approximately $4,628,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.